Literature DB >> 17059882

Immunohistochemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with kava extract.

Natasha P Clayton1, Katsuhiko Yoshizawa, Grace E Kissling, Leo T Burka, Po-Chuen Chan, Abraham Nyska.   

Abstract

Kava (Piper methysticum), used for relaxation and pain relief, has been one of the leading dietary supplements and several reports linking hepatic functional disturbances and liver failure to kava have resulted in a ban on sales in Europe and Canada and the issuance of warnings by the US FDA. The National Toxicology Program conducted 14-week rat studies to characterize the toxicology of kava exposure in Fischer 344 rats [National Toxicity Program. 90 day gavage toxicity studies of KAVA KAVA EXTRACT in Fischer rats and B6C3F1 mice. Research Triangle Park, NC; 2005a; National Toxicity Program. Testing status of agents at NTP (KAVA KAVA EXTRACT M990058). Research Triangle Park, NC; 2005b. (http://ntp.niehs.nih.gov/index.cfm?objectid=071516E-C6E1-7AAA-C90C751E23D14C1B)]. Groups of 10 male and 10 female rats were administered kava extract by gavage at 0, 0.125, 0.25, 0.5, 1.0, and 2.0 g/kg/day. Increased gamma-glutamyl-transpeptidase (GGT) activities were observed in the 2.0 g/kg males and 1.0 and 2.0 g/kg females, as well as increased serum cholesterol levels in males and females at 0.5 g/kg and higher. Increases in incidence and severity of hepatocellular hypertrophy (HP) were noted in males at 1.0 g/kg and females at 0.5 g/kg and higher, as well as increased liver weights. Immunohistochemical analyses of the expression of cytochrome-P450 (CYP) enzymes in liver of the control and 1.0- and 2.0-g/kg-treated groups indicated decreased expression of CYP2D1 (human CYP2D6 homolog) in 2.0 g/kg females and increased expression of CYP1A2, 2B1, and 3A1 in 1.0 and 2.0 g/kg groups of both sexes. The no observed adverse effect levels were decided as 0.25 g/kg in both genders, based on neurotoxic effects, increases in GGT, cholesterol, liver weight, and HP and decreases in body weight. Kava-induced hepatic functional changes in the F344 rat might be relevant to human clinical cases of hepatotoxicity following exposure.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17059882      PMCID: PMC1839869          DOI: 10.1016/j.etp.2006.08.002

Source DB:  PubMed          Journal:  Exp Toxicol Pathol        ISSN: 0940-2993


  47 in total

Review 1.  Quality review procedures necessary for rodent pathology databases and toxicogenomic studies: the National Toxicology Program experience.

Authors:  Gary A Boorman; Joseph K Haseman; Michael D Waters; Jerry F Hardisty; Robert C Sills
Journal:  Toxicol Pathol       Date:  2002 Jan-Feb       Impact factor: 1.902

Review 2.  Liver enzyme alteration: a guide for clinicians.

Authors:  Edoardo G Giannini; Roberto Testa; Vincenzo Savarino
Journal:  CMAJ       Date:  2005-02-01       Impact factor: 8.262

3.  Induction of cytochrome P450 isozymes by phenobarbital in pregnant rat and fetal livers and placenta.

Authors:  Noriko Ejiri; Kei-ichi Katayama; Kunio Doi
Journal:  Exp Mol Pathol       Date:  2005-04       Impact factor: 3.362

4.  Genetic polymorphism of debrisoquine (CYP2D6) and proguanil (CYP2C19) in South Pacific Polynesian populations.

Authors:  S Wanwimolruk; S Bhawan; P F Coville; S C Chalcroft
Journal:  Eur J Clin Pharmacol       Date:  1998-07       Impact factor: 2.953

5.  Inhibition of human cytochrome P450 activities by kava extract and kavalactones.

Authors:  James M Mathews; Amy S Etheridge; Sherry R Black
Journal:  Drug Metab Dispos       Date:  2002-11       Impact factor: 3.922

Review 6.  Liver function tests: their role in the diagnosis of hepatobiliary diseases.

Authors:  Joseph A Knight
Journal:  J Infus Nurs       Date:  2005 Mar-Apr

7.  Altered expression of cytochrome P450 and possible correlation with preneoplastic changes in early stage of rat hepatocarcinogenesis.

Authors:  Lin-lin Liu; Li-kun Gong; Xin-ming Qi; Yan Cai; Hui Wang; Xiong-fei Wu; Ying Xiao; Jin Ren
Journal:  Acta Pharmacol Sin       Date:  2005-06       Impact factor: 6.150

Review 8.  Sex-dependent metabolism of xenobiotics.

Authors:  C A Mugford; G L Kedderis
Journal:  Drug Metab Rev       Date:  1998-08       Impact factor: 4.518

Review 9.  Kava extracts: safety and risks including rare hepatotoxicity.

Authors:  R Teschke; W Gaus; D Loew
Journal:  Phytomedicine       Date:  2003       Impact factor: 5.340

Review 10.  Kava: an overview.

Authors:  Y N Singh
Journal:  J Ethnopharmacol       Date:  1992-08       Impact factor: 4.360

View more
  13 in total

Review 1.  Gene expression profiling as an initial approach for mechanistic studies of toxicity and tumorigenicity of herbal plants and herbal dietary supplements.

Authors:  Lei Guo; Nan Mei; Qingsu Xia; Tao Chen; Po-Chuen Chan; Peter P Fu
Journal:  J Environ Sci Health C Environ Carcinog Ecotoxicol Rev       Date:  2010-01       Impact factor: 3.781

2.  Ginkgo biloba extract induces gene expression changes in xenobiotics metabolism and the Myc-centered network.

Authors:  Lei Guo; Nan Mei; Wayne Liao; Po-Chuen Chan; Peter P Fu
Journal:  OMICS       Date:  2010-02

3.  Liver toxicity and carcinogenicity in F344/N rats and B6C3F1 mice exposed to Kava Kava.

Authors:  Mamta Behl; Abraham Nyska; Rajendra S Chhabra; Gregory S Travlos; Laurene M Fomby; Barney R Sparrow; Milton R Hejtmancik; Po C Chan
Journal:  Food Chem Toxicol       Date:  2011-08-18       Impact factor: 6.023

4.  Methysticin and 7,8-dihydromethysticin are two major kavalactones in kava extract to induce CYP1A1.

Authors:  Yan Li; Hu Mei; Qiangen Wu; Suhui Zhang; Jia-Long Fang; Leming Shi; Lei Guo
Journal:  Toxicol Sci       Date:  2011-09-09       Impact factor: 4.849

5.  Gene expression profiling in male B6C3F1 mouse livers exposed to kava identifies--changes in drug metabolizing genes and potential mechanisms linked to kava toxicity.

Authors:  Lei Guo; Qiang Shi; Stacey Dial; Qingsu Xia; Nan Mei; Quan-zhen Li; Po-Chuen Chan; Peter Fu
Journal:  Food Chem Toxicol       Date:  2009-12-03       Impact factor: 6.023

6.  Identification of methysticin as a potent and non-toxic NF-kappaB inhibitor from kava, potentially responsible for kava's chemopreventive activity.

Authors:  Ahmad Ali Shaik; David Lee Hermanson; Chengguo Xing
Journal:  Bioorg Med Chem Lett       Date:  2009-08-06       Impact factor: 2.823

7.  Clinical assessment of CYP2D6-mediated herb-drug interactions in humans: effects of milk thistle, black cohosh, goldenseal, kava kava, St. John's wort, and Echinacea.

Authors:  Bill J Gurley; Ashley Swain; Martha A Hubbard; D Keith Williams; Gary Barone; Faith Hartsfield; Yudong Tong; Danielle J Carrier; Shreekar Cheboyina; Sunil K Battu
Journal:  Mol Nutr Food Res       Date:  2008-07       Impact factor: 5.914

8.  Analysis of gene expression changes of drug metabolizing enzymes in the livers of F344 rats following oral treatment with kava extract.

Authors:  Lei Guo; Quanzhen Li; Qingsu Xia; Stacey Dial; Po-Chuen Chan; Peter Fu
Journal:  Food Chem Toxicol       Date:  2008-12-07       Impact factor: 6.023

Review 9.  Toxicity of kava kava.

Authors:  Peter P Fu; Qingsu Xia; Lei Guo; Hongtao Yu; Po-Chuen Chan
Journal:  J Environ Sci Health C Environ Carcinog Ecotoxicol Rev       Date:  2008 Jan-Mar       Impact factor: 3.781

Review 10.  The toxicologic pathology aspects of selected natural herbal products and related compounds.

Authors:  Ruba Ibrahim; Abraham Nyska; June Dunnick; Yuval Ramot
Journal:  J Toxicol Pathol       Date:  2021-03-29       Impact factor: 1.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.